Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

799.90 +12.68 (+1.61%)
Official Closing Price Updated: 7:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
Some investors may be eyeing potential gains from the company's dividends. Here's how you can earn $500 monthly from Eli Lilly. 
Via Benzinga
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy. 
Via The Motley Fool
Novo Nordisk Tumbles 3% In Wednesday Premarket: What's Causing 'Miracle' Weight Loss Drug Ozempic Maker's Stock Slide?
The dip in Novo Nordisk's shares comes despite deep-pocketed investors were adopting a bullish approach. 
Via Benzinga
Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years
Eli Lilly is one of the most innovative pharmaceutical companies right now. 
Via The Motley Fool
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Should You Buy Eli Lilly Before Aug. 8?
There's reason to be optimistic about what's to come. 
Via The Motley Fool
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These tried-and-true businesses can deliver returns to investors for many years to come. 
Via The Motley Fool
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly's Zepbound and Novo Nordisk's Wegovy face supply shortages, influencing doctors' prescribing habits. Both companies are investing heavily to meet demand in the lucrative U.S. market. 
Via Benzinga
After Ozempic And Botox, Hollywood Is Going Gaga Over This New Anti-Aging Supplement
This trend is gaining momentum although its effectiveness is yet to be determined. 
Via Benzinga
THQ: A Favorite Pharma Fund
Medical spending is set to rise as an increasing proportion of the US population crosses the retirement age. Spending is projected to grow an average of 5.6% a year through 2032. The abrdn Healthcare... 
Via Talk Markets
Topics Retirement
Exposures Pension
These 2 Simple ETFs Could Turn $500 a Month Into $1 Million.
Learn how $500 a month can grow into a sizable nest egg. 
Via The Motley Fool
Topics ETFs
Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?
Recent results from a clinical trial show that treatment with Zepbound significantly reduced patients' risk of heart failure outcomes, including cardiovascular death. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market. 
Via The Motley Fool
Is This Decision by Pfizer Bad News for Eli Lilly?
Lilly's revenue gains have helped its stock to roar higher. 
Via The Motley Fool
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Psychologists warn of increased eating disorders linked to popular GLP-1 weight loss drugs like Wegovy and Zepbound. Experts urge better screening and research to address potential risks. 
Via Benzinga
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin improved significantly due to reduced costs and higher selling prices.... 
Via Benzinga
What's Going On With Eli Lilly and Company Shares Friday
Eli Lilly is anticipated to release earnings on August 8 for the 2024 fiscal year second quarter. 
Via Benzinga
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users. 
Via Investor's Business Daily
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The innovative biotech is looking for its next blockbuster. 
Via The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
Why Eli Lilly Stock Trounced the Market on Thursday
What's good for Zepbound is good for the company, it seems. 
Via The Motley Fool
What's Going On With HIMS Shares Today?
Hims & Hers Health experienced a significant decline in its stock price on Thursday. Here's what you need to know. 
Via Benzinga
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Anti-obesity therapeutics are all the rage and for good reason. Investors seeking to profit should consider these weight loss stocks. 
Via InvestorPlace
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
Eli Lilly's SUMMIT phase 3 trial shows tirzepatide significantly reduces heart failure risk in adults with HFpEF and obesity. Tirzepatide achieved primary and secondary endpoints, including improved... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.